X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac disease.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ImmunogenX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 14, 2024
Details:
Through the agreement, the company will prioritize the clinical development of FW-UP (niclosamide), currently undergoing Phase I/II clinical trial studies for the treatment of ulcerative colitis.
Lead Product(s): Niclosamide
Therapeutic Area: Gastroenterology Product Name: FW-UP
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 27, 2023
Details:
Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac disease.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ImmunogenX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 18, 2023
Details:
Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.
Lead Product(s): Capeserod
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 14, 2023
Details:
FW-EPI (adrulipase) is an oral administered, recombinant lipase enzyme, non-systemic biologic capsule for the treatment of EPI associated with CF and CP. It is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
FW-EPI (adrulipase) is an oral administered, recombinant lipase enzyme, non-systemic biologic capsule for the treatment of EPI associated with CF and CP. It is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
FW-EPI (adrulipase) is an oral administered, recombinant lipase enzyme, non-systemic biologic capsule for the treatment of EPI associated with CF and CP. It is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
FW-EPI (adrulipase) is an oral administered, recombinant lipase enzyme, non-systemic biologic capsule for the treatment of EPI associated with CF and CP. It is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule which is designed to break up fat molecules in the digestive tract of EPI patients for the treatment of EPI associated with CF and CP.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule which is designed to break up fat molecules in the digestive tract of EPI patients for the treatment of EPI associated with CF and CP.
Lead Product(s): Adrulipase
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: FW-EPI
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
